Pharmacodynamic implications for use of antifungal agents

Current Opinion in Pharmacology

Volumn 7, Issue 5, 2007, Pages 491-497

  Lewis, Russell E ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; STEROL 14ALPHA DEMETHYLASE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CRITICALLY ILL PATIENT; CRYPTOCOCCAL MENINGITIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG USE; ESOPHAGUS CANDIDIASIS; FATALITY; FUNGICIDAL ACTIVITY; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; NONHUMAN; OROPHARYNX CANDIDIASIS; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; FLUCYTOSINE; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYENES; TRIAZOLES;

EID: 35248888907     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.05.004     Document Type: Review

References (49)

1. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard NCCLS document M27-A2 (2002), National Committee for Clinical Laboratory Standards, Wayne, PA
2. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard NCCLS document M38-A (2002), National Committee for Clinical Laboratory Standards, Wayne, PA
3. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 20 (2006) 679-697
4. Meletiadis J., Petraitis V., Petraitiene R., Lin P., Stergiopoulou T., Kelaher A.M., Sein T., Schaufele R.L., Bacher J., and Walsh T.J. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 194 (2006) 1008-1018
5. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., and Drusano G.L. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44 (2007) 79-86
6. Sohnle P.G., Hahn B.L., and Erdmann M.D. Effect of fluconazole on viability of Candida albicans over extended periods of time. Antimicrob Agents Chemother 40 (1996) 2622-2625
7. Gubbins P.O., McConnell S.A., and Amsden J.R. Antifungal agents. In: Piscitelli S.C., and Rodvold K.A. (Eds). Drug Interactions in Infectious Diseases. edn 2 (2005), Humana Press 289-338
8. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 47 (2003) 1179-1186
9. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2 (2004) 289-300
10. Rex J.H., Pfaller M.A., Walsh T.J., Chaturvedi V., Espinel-Ingroff A., Ghannoum M.A., Gosey L.L., Odds F.C., Rinaldi M.G., Sheehan D.J., et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14 (2001) 643-658
11. Glasmacher A., Hahn C., Leutner C., Molitor E., Wardelmann E., Losem C., Sauerbruch T., Marklein G., and Schmidt-Wolf I.G.H. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42 (1999) 443-451
12. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Ruhnke M., and Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 (2002) 563-571
13. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill R., Greene R.E., Hachem R., Hadley S., Herbrecht R., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12. An open-label salvage study of posaconazole for patients with aspergillosis who were refractory or intolerant to other antifungal agents. This was the first clinical trial to provide evidence of a correlation between plasma concentrations of posaconazole and clinical response in humans.
14. Groll A.H., and Walsh T.J. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 49 Suppl 1 (2006) 7-16
15. Schering-Plough Inc.: Noxafil (posaconazole) Oral suspension. New Drug Application; URL: www.fda.gov/cder. 2006.
16. Meletiadis J., Chanock S., and Walsh T.J. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev 19 (2006) 763-787
17. Trifilio S., Pennick G., Pi J., Zook J., Golf M., Kaniecki K., Singhal S., Williams S., Winter J., Tallman M., et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109 (2007) 1532-1535. A retrospective analysis of plasma voriconazole trough concentrations in hematopoietic stem cell transplant recipients that demonstrated no consistent relationship between drug doses and plasma concentrations. This study suggests that therapeutic drug monitoring should be considered in patients receiving voriconazole therapy.
18. Groll A.H., Gea-Banacloche J.C., Glasmacher A., Just-Nuebling G., Maschmeyer G., and Walsh T.J. Clinical pharmacology of antifungal compounds. Infect Dis Clin N Amer 17 (2003) 159-191 IX
19. max/MIC with treatment outcome.
20. Andes D., Stamsted T., and Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 45 (2001) 922-926
21. max/MIC is the parameter that most closely correlated with AMB-clearance of Aspergillus from the lung. Evidence of a steep-dose response, however, was not seen at plasma concentrations above 1 μg/mL.
22. Bekersky I., Fielding R.M., Dressler D.E., Lee J.W., Buell D.N., and Walsh T.J. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46 (2002) 828-833
23. Christiansen K.J., Bernard E.M., Gold J.W.M., and Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 152 (1985) 1037-1043
24. Collette N., van der Auwera P., Pascual Lopez A., Heymans C., and Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 33 (1989) 362-368
25. Lewis R.E., and Wiederhold N.P. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?. Clin Infect Dis 37 (2003) 871-872
26. Hong Y., Shaw P.J., Nath C.E., Yadav S.P., Stephen K.R., Earl J.W., and McLachlan A.J. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 50 (2006) 935-942
27. Andes D., and van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 44 (2000) 938-942. The first in vivo study to demonstrate the primarily time-dependent pharmacodynamics of flucytosine against Candida species.
28. Lewis R.E., Klepser M.E., and Pfaller M.A. In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagn Microbiol Infect Dis 36 (2000) 101-105
29. Stamm A.M., Diasio R.B., Dismukes W.E., Shadomy S., Cloud G.A., Bowles C.A., Karam G.H., and Espinel-Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 83 (1987) 236-242
30. Denning D.W. Echinocandins: a new class of antifungal. J Antimicrob Chemother 49 (2002) 881-889
31. Stone E.A., Fung H.B., and Kirschenbaum H.L. Caspofungin: an echinocandin antifungal agent. Clin Ther 24 (2002) 351-377
32. Chandrasekar P.H., and Sobel J.D. Micafungin: a new echinocandin. Clin Infect Dis 42 (2006) 1171-1178
33. Raasch R.H. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2 (2004) 499-508
34. Andes D., Marchillo K., Lowther J., Bryskier A., Stamstad T., and Conklin R. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 47 (2003) 1187-1192
35. Louie A., Deziel M., Liu W., Drusano M.F., Gumbo T., and Drusano G.L. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49 (2005) 5058-5068. The first dosage-fractionated pharmacodynamic study of an echinocandin that demonstrated the importance of persistent tissue concentrations (in the kidney) for understanding echinocandin activity.
36. Gumbo T., Drusano G.L., Liu W., Ma L., Deziel M.R., Drusano M.F., and Louie A. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 50 (2006) 3695-3700
37. max/MEC ratio of 10. Interestingly, a strong paradoxical effect was observed at higher drug exposures, irrespective of the dosing frequency.
38. Gumbo T., Drusano G.L., Liu W., Kulawy R.W., Fregeau C., Hsu V., and Louie A. Once a week micafungin therapy is as effective as daily therapy for disseminated Candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 51 (2007) 968-974. The first study to demonstrate the efficacy of infrequently administered, large echinocandin doses in a persistently neutropenic mouse model of invasive candidiasis.
39. Buell D, Kovanda L, Drake T, Frisco C.: Alternative day dosing of micafungin for esophageal Candidiasis. Abstract M-79. In 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society for Microbiology; 2005.
40. Clemons K.V., Espiritu M., Parmar R., and Stevens D.A. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 50 (2006) 1293-1297
41. Stevens D.A., Espiritu M., and Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48 (2004) 3407-3411
42. Stevens D.A., White T.C., Perlin D.S., and Selitrennikoff C.P. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51 (2005) 173-178
43. Stevens D.A., Ichinomiya M., Koshi Y., and Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 50 (2006) 3160-3161. First study to specifically describe an association between the echinocandin paradoxical effect and increases in cell wall chitin.
44. Wiederhold N.P., Kontoyiannis D.P., Prince R.A., and Lewis R.E. Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 49 (2005) 5146-5148. The first study to describe the relationship of a homestatic cell wall stress response pathway with the paradoxical effect of caspofungin in Candida species. The paradoxical effect was diminished in homozygous mkc1 knockout isolates compared with wild type and was further suppressed by cyclosporin, implicating a role for the calcineurin pathway.
45. Andes D., and van Ogtrop H. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43 (1999) 2116-2120. The first in vivo study to identify AUC/MIC as the pharmacodynamic parameter most closely associated with fluconazole activity in Candida species.
46. Louie A., Drusano G.L., Banerjee P., Liu Q.F., Liu W.G., Kaw P., Shayegani M., Taber H., and Miller M.H. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 42 (1998) 1105-1109
47. Andes D., Marchillo K., Stamstad T., and Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47 (2003) 3165-3169
48. Andes D., Marchillo K., Conklin R., Krishna G., Ezzet F., Cacciapuoti A., and Loebenberg D. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 48 (2004) 137-142
49. max/MIC as the pharmacodynamic parameter most closely associated with echinocandin activity in Candida species.